You’ve come this far – don’t stop now. Take one more step for additional protection.
NERLYNX® is indicated for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.
Extended adjuvant treatment with NERLYNX®
reduces the risk of HER2+/HR+ breast cancer recurrence by 51% after 2 years*†‡
Safety
Learn about NERLYNX® common adverse events, diarrhoea management and other safety information.